Leukemia & Lymphoma Society | Discovery Grant Program


Event details

Date 29.09.2023
Category Call for proposal
Aim:  The Leukemia & Lymphoma Society, Inc. (LLS) is a national voluntary health agency dedicated to the conquest of hematologic malignancies and relevant premalignant conditions.   The Discovery Grant Program is a research award program designed to encourage basic research, technological innovation, and informatics pipeline development.

Examples of projects of potential interest include:
  • cellular activities that underlie the behavior and vulnerabilities of blood cancer cells including phenomena or processes such as clonal evolution, autophagy, unique metabolic vulnerabilities, inflammation/inflammasomes, DNA damage responses, organellar changes, and poorly understood cellular regulatory mechanisms
  • resistance mechanisms including immune evasion, resistant clone evolution, and cellular changes underlying development of resistance to chemotherapies
  • novel biomarkers or techniques to detect and monitor blood cancer development and progression
  • blood cancer cell interactions with the microenvironment and with the immune system, including exploration of novel immune synapses

Funding:       $750,000

Duration:      3 years

Eligibility:    The program welcomes applications from US citizens and non-US citizens, as well as applicants who are performing research outside the United States. Applicants must hold a PhD, MD, DVM, or equivalent degree. Applicants must be independent investigators affiliated with a non-profit institution at the time funding commences and for the duration of the award. Further, they must be established investigators, defined as having more than 3 years in an independent faculty appointment at the time of the Letter of Intent.

How to Apply: The 2-stage application process begins with a Letter of Intent, to be submitted on the LLS Research Portal at https://lls.fluxx.io/. LOIs should provide brief descriptions of how the goals and/or approaches are novel and innovative, and what impact the research may have on blood cancer. All LOIs will be reviewed, and those judged to be the most promising, competitive, and responsive to the goals of the program will be invited to submit a full application.  At the full application stage, an Institutional signature is required; please contact the Research Office for this step. Applicants will be notified of the final outcomes by June 2024.

Deadline:      Letter of Intent – 29 September 2023 (3PM ET)
                        Full Application – 04 March 2024 (3PM ET)

Further information
  • More information about the program, guidelines, and instructions are available here
  • The application portal can be found here
  • For any other questions, please contact the Research Office

Practical information

  • General public
  • Free


Event broadcasted in